Liver cancer remains a leading cause of cancer-related mortality globally. With approximately 75–85% of liver cancers attributed to Hepatocellular Carcinoma (HCC), and a 5-year survival rate of less than 20%, effective treatment options are critical. Among the various therapies, transarterial chemoembolization (TACE) and bland embolization (TAE) play vital roles, particularly in intermediate-stage HCC. TACE combines chemotherapy with embolic agents to enhance local drug delivery while inducing ischemic necrosis, offering a promising bridge to liver transplantation or other curative treatments. TAE focuses on occluding the tumor’s blood supply, providing a viable alternative option. Current practices in TACE, including drug-eluting beads (DEB-TACE), have shown improved patient outcomes and tumor response, with a notable reduction in systemic side effects. Combination therapies involving TACE or TAE with other modalities, such as tumor ablations, kinase inhibitors, and immunotherapy, are being explored to enhance efficacy and reduce recurrence. Ongoing clinical trials are refining these techniques, aiming to further optimize patient outcomes. The future of embolization therapies lies in advancements in targeted drug delivery systems, personalized therapeutics, and the integration of innovative technologies like artificial intelligence to improve treatment precision and patient outcomes.